Zynex Inc Stock Price, News & Analysis

Intrinsic LLC, a valuation and transaction advisory firm, announced it issued two fairness opinions for publicly traded clients in 2022. The firm provided an opinion to Zynex Inc. (Nasdaq: ZYXI) affirming that $31 million for acquiring Kestrel Labs was fair. Additionally, for FG Merger Corp (Nasdaq: FGMC), it deemed $100 million in a merger with iCoreConnect, Inc. fair. Intrinsic's Transaction Opinions practice supports Boards of Directors in fulfilling fiduciary duties, particularly amid evolving legal and regulatory landscapes. The firm is bolstered by a team with extensive experience in rendering fiduciary opinions across various sectors.

Zynex, Inc. (NASDAQ: ZYXI) has announced a community blood donation drive to be held on February 1, 2023, at its Englewood, CO headquarters in partnership with Vitalant. This initiative aims to address the critical shortage of blood while providing a unique opportunity for research. Participants will be monitored using Zynex's CM-1600 system during the donation, contributing to an IRB-approved clinical trial assessing the system's efficacy in detecting blood loss. The CM-1600 is currently under FDA review, building upon the CM-1500, which received FDA clearance in February 2020.

Zynex, Inc. (Nasdaq: ZYXI) has been recognized in The Power 500 Healthcare Technology Companies, ranking 27th among medical device firms. This accolade underscores Zynex's role as a leader in the healthcare technology sector, particularly in non-invasive medical devices for pain management and rehabilitation. CEO Thomas Sandgaard emphasized that this recognition is a testament to the company's operational performance and commitment to improving patient health. Zynex aims for continued innovation and growth in its offerings.

Zynex, Inc. (NASDAQ: ZYXI) reported record order growth for Q4 2022, with orders increasing by 48% compared to Q4 2021. This significant growth resulted in a 23% increase in full-year orders. CEO Thomas Sandgaard highlighted a 11% rise in orders over Q3 2022 as well. The company confirmed expected Q4 revenue between $48.0-$51.0 million and adjusted EBITDA of $10.0-$12.0 million. For the full year, revenue estimates are between $157.4-$160.4 million and adjusted EBITDA between $26.7-$28.7 million. The positive financial performance underscores Zynex's strong sales strategy and product demand.

Zynex, a medical technology company, announced a new $10 million share buyback program effective from November 1, 2022, to October 31, 2023. This move follows a prior $20 million repurchase already conducted in 2022. CEO Thomas Sandgaard stated the buyback reflects the company's strong balance sheet and aims to enhance shareholder value. The buyback will be executed under SEC regulations and is expected to be funded by existing cash without materially impacting capital levels. As of November 1, 2022, Zynex had 41.6 million shares issued.

Zynex, Inc. (Nasdaq: ZYXI) reported strong third-quarter 2022 results, achieving a 19% revenue increase year-over-year to $41.5 million. The company posted a net income of $4.9 million with a diluted EPS of $0.13 and an Adjusted EBITDA of $8.1 million. Cash from operations was $7.4 million. Zynex completed a $10 million share buyback, totaling $20 million year-to-date. Guidance for Q4 estimates revenue between $48-$51 million, anticipating a 23% increase from Q4 2021.

Zynex, Inc. (NASDAQ: ZYXI) will report its third quarter 2022 financial results on October 27, 2022, at 4:15 p.m. ET. A conference call and webcast will follow to discuss the results and provide corporate updates. Founded in 1996, Zynex specializes in non-invasive medical devices for pain management and rehabilitation. This announcement is part of their regular updates on financial performance.